Related Experiment Video
Updated: Aug 26, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
Thomas W Martens1, Bimal V Patel2, Sharon M Wang3
1International Diabetes Center, HealthPartners, Minneapolis, MN.
Objective:
To evaluate the effect of using the t:slim X2 insulin pump with Control-IQ technology (hereafter, Control-IQ ; Tandem Diabetes Care, Inc) on glycemic status in individuals with type 2 diabetes (T2D) who switched from multiple daily insulin injections.
Study Design:
This 12-month retrospective analysis utilized data from the Tandem t:connect web application and customer relationship management database, encompassing individuals covered by commercial insurers, Medicaid, and Medicare.
Methods:
We assessed changes in glucose management indicator (GMI) values from baseline hemoglobin A 1c (HbA 1c ) at 12 months relative to Healthcare Effectiveness Data and Information Set (HEDIS) quality measures (HbA 1c or GMI: < 8.0% [in control] and > 9.0% [poor control]). The primary outcome was the proportion of individuals who met the recommended HEDIS measure. Achievement of a GMIof less than 7.0% was included as a secondary outcome. Changes in glycemic outcomes and the proportion of individuals meeting the national threshold were analyzed.
Results:
The analysis included 1737 individuals with T2D who had baseline HbA 1c data. Following initiation of Control-IQ, the number of individuals who met the HEDIS (GMI < 8.0%) measure increased from 755 (43.5%) at baseline to 1545 (88.9%) at 12 months (∆ = 104.6%). The number of individuals who achieved a GMI of less than 7% increased from 282 (16.2%) to 678 (39.0%) (∆ = 140.4%). The number of individuals with HbA 1c greater than 9.0% at baseline decreased from 514 (29.6%) at baseline to 10 (0.6%) (∆ = -98.1%) at 12 months.
Conclusions:
A greater proportion of individuals who transitioned to Control-IQ therapy achieved the HEDIS goal for in-control diabetes across all payer types, as measured by GMI.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...